| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
25006 |
| Drug |
Amivantamabin in combination with lazertinib |
| Brand |
Rybrevant®) in combination with Lazcluze® |
| Indication |
Amivantamab in combination with lazertinib is indicated for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. |
| Rapid review commissioned |
28/01/2025 |
| Rapid review completed |
05/03/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amivantamab in combination with lazertinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
26/03/2025 |
| Pre-submission consultation with Applicant |
30/04/2025 |
| Full submission received from Applicant |
01/08/2025 |
